{"nctId":"NCT03751631","briefTitle":"Safety and Efficacy of Phenylephrine 2.5%-Tropicamide 1% Microdose Ophthalmic Solution for Pupil Dilation","startDateStruct":{"date":"2018-11-15","type":"ACTUAL"},"conditions":["Mydriasis"],"count":70,"armGroups":[{"label":"1-TR/PE, 2-TR, 3-PE","type":"OTHER","interventionNames":["Drug: Tropicamide 1%-Phenylephrine 2.5% ophthalmic solution (TR/PE)","Drug: Tropicamide 1% ophthalmic solution (TR)","Drug: Phenylephrine 2.5% ophthalmic solution (PE)"]},{"label":"1-TR/PE, 2-PE, 3-TR","type":"OTHER","interventionNames":["Drug: Tropicamide 1%-Phenylephrine 2.5% ophthalmic solution (TR/PE)","Drug: Tropicamide 1% ophthalmic solution (TR)","Drug: Phenylephrine 2.5% ophthalmic solution (PE)"]},{"label":"1-TR, 2-TR/PE, 3-PE","type":"OTHER","interventionNames":["Drug: Tropicamide 1%-Phenylephrine 2.5% ophthalmic solution (TR/PE)","Drug: Tropicamide 1% ophthalmic solution (TR)","Drug: Phenylephrine 2.5% ophthalmic solution (PE)"]},{"label":"1-TR, 2-PE, 3-TR/PE","type":"OTHER","interventionNames":["Drug: Tropicamide 1%-Phenylephrine 2.5% ophthalmic solution (TR/PE)","Drug: Tropicamide 1% ophthalmic solution (TR)","Drug: Phenylephrine 2.5% ophthalmic solution (PE)"]},{"label":"1-PE, 2-TR/PE, 3-TR","type":"OTHER","interventionNames":["Drug: Tropicamide 1%-Phenylephrine 2.5% ophthalmic solution (TR/PE)","Drug: Tropicamide 1% ophthalmic solution (TR)","Drug: Phenylephrine 2.5% ophthalmic solution (PE)"]},{"label":"1-PE, 2-TR, 3-TR/PE","type":"OTHER","interventionNames":["Drug: Tropicamide 1%-Phenylephrine 2.5% ophthalmic solution (TR/PE)","Drug: Tropicamide 1% ophthalmic solution (TR)","Drug: Phenylephrine 2.5% ophthalmic solution (PE)"]}],"interventions":[{"name":"Tropicamide 1%-Phenylephrine 2.5% ophthalmic solution (TR/PE)","otherNames":["Mydcombi"]},{"name":"Tropicamide 1% ophthalmic solution (TR)","otherNames":[]},{"name":"Phenylephrine 2.5% ophthalmic solution (PE)","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Ability to provide written consent and return for all study visits\n* Photopic pupil diameter \\<= 3.5 mm in each eye\n\nExclusion Criteria:\n\n* Allergy to phenylephrine hydrochloride, tropicamide, or benzalkonium chloride\n* History of benign prostatic hyperplasia\n* Use of a benzodiazepine, monoamine oxidase inhibitor, tricyclic antidepressant, anticonvulsant, or cholinergic drug\n* History of closed-angle glaucoma\n* Anatomically narrow anterior chamber angles\n* Ocular surgery or laser treatment of any kind\n* History of chronic or acute uveitis\n* History of traumatic iritis or hyphema\n* History of traumatic mydriasis or angle recession\n* History of heterochromia\n* Irregularly-shaped pupil secondary to ocular trauma or congenital defect.\n* History of neurogenic pupil disorder\n* History of anterior chamber intraocular lens (IOL) or iris-fixated IOL\n* History of iris surgery, iris atrophy, or iris-cornea apposition/touch\n* Unwilling or unable to discontinue use of contact lenses at treatment visits.\n* Current active eye disease for which topical or systemic ophthalmic medication is necessary, except for dry eye disease managed using artificial tears.\n* Presence of a severe/serious ocular condition, or any other unstable medical condition that, in the Investigator's opinion, may preclude study treatment and/or follow-up\n* Pregnancy or lactation","healthyVolunteers":true,"sex":"ALL","stdAges":["CHILD","ADULT","OLDER_ADULT"]},"locations":{"multicenter":false},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Change in Pupil Diameter From Baseline","description":"Difference in 35-minute pupil diameter vs. baseline measured using pupillometry in highly photopic conditions.\n\nPupil diameter is reported in millimeters. For the change in pupil diameter, larger measurements indicate a better outcome.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2.672","spread":"0.5673"},{"groupId":"OG001","value":"2.583","spread":"0.4674"},{"groupId":"OG002","value":"2.657","spread":"0.6016"},{"groupId":"OG003","value":"2.569","spread":"0.5211"},{"groupId":"OG004","value":"2.651","spread":"0.5749"},{"groupId":"OG005","value":"2.584","spread":"0.5344"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"7.301","spread":"0.8943"},{"groupId":"OG001","value":"7.329","spread":"0.9771"},{"groupId":"OG002","value":"6.762","spread":"0.8619"},{"groupId":"OG003","value":"6.690","spread":"0.8682"},{"groupId":"OG004","value":"3.388","spread":"0.8950"},{"groupId":"OG005","value":"3.552","spread":"0.9340"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"4.629","spread":"0.8343"},{"groupId":"OG001","value":"4.746","spread":"0.8173"},{"groupId":"OG002","value":"4.105","spread":"0.7207"},{"groupId":"OG003","value":"4.121","spread":"0.6839"},{"groupId":"OG004","value":"0.737","spread":"0.7939"},{"groupId":"OG005","value":"0.969","spread":"0.8943"}]}]}]},{"type":"OTHER_PRE_SPECIFIED","title":"Percentage of Eyes Achieving Pupil Diameter 6.0 mm or Larger After Receipt of Each Medication","description":"The percent of eyes with pupil diameter 6.0 mm or larger as measured using pupillometry in highly photopic conditions. As this is a cross-over study, each of the 62 participants received each medication. Data is reported separately for the right and left eyes of the 62 participants. A higher percentage indicates a better outcome.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"95.2","spread":null},{"groupId":"OG001","value":"93.5","spread":null},{"groupId":"OG002","value":"79.0","spread":null},{"groupId":"OG003","value":"77.4","spread":null},{"groupId":"OG004","value":"1.6","spread":null},{"groupId":"OG005","value":"1.6","spread":null}]}]}]},{"type":"OTHER_PRE_SPECIFIED","title":"Percentage of Eyes Achieving Pupil Diameter 7.0 mm or Larger After Receipt of Each Medication","description":"The percent of eyes with pupil diameter 7.0 mm or larger as measured using pupillometry in highly photopic conditions. As this is a cross-over study, each of the 62 participants received each medication. Data is reported separately for the right and left eyes of the 62 participants. A higher percentage indicates a better outcome.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"67.7","spread":null},{"groupId":"OG001","value":"67.7","spread":null},{"groupId":"OG002","value":"43.5","spread":null},{"groupId":"OG003","value":"41.9","spread":null},{"groupId":"OG004","value":"0","spread":null},{"groupId":"OG005","value":"0","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":0,"n":62},"commonTop":["Vision blurred","Visual acuity reduced","Vital dye staining cornea present","Eye pain"]}}}